These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26399136)

  • 1. Orkambi's Slick Unveiling Puts Insurers in a Bind.
    Silverman E
    Manag Care; 2015 Aug; 24(8):16-7. PubMed ID: 26399136
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 3. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 4. Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi.
    Hollis A
    Healthc Policy; 2019 Aug; 15(1):70-80. PubMed ID: 31629457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genericisation in cost-effectiveness analysis of cystic fibrosis medicines.
    Beattie A; Moore A; Ramagopalan SV
    Lancet; 2024 Jun; 403(10444):2591-2592. PubMed ID: 38879249
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 7. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
    Cohen D; Raftery J
    BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
    [No Abstract]   [Full Text] [Related]  

  • 8. The effectiveness and value of novel treatments for cystic fibrosis.
    Tice JA; Kuntz KM; Wherry K; Seidner M; Rind DM; Pearson SD
    J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
    [No Abstract]   [Full Text] [Related]  

  • 9. Pricing for orphan drugs: will the market bear what society cannot?
    O'Sullivan BP; Orenstein DM; Milla CE
    JAMA; 2013 Oct; 310(13):1343-4. PubMed ID: 24084916
    [No Abstract]   [Full Text] [Related]  

  • 10. Cystic Fibrosis Trust's clarification of Cohen and Raftery's article on cystic fibrosis drug development.
    Owen E
    BMJ; 2014 Mar; 348():g1849. PubMed ID: 24603568
    [No Abstract]   [Full Text] [Related]  

  • 11. A new model for drug development using a multi-stakeholder consortium.
    Hall AK
    BMJ; 2014 Mar; 348():g1850. PubMed ID: 24603569
    [No Abstract]   [Full Text] [Related]  

  • 12. Promising gene therapies pose million-dollar conundrum.
    Check Hayden E
    Nature; 2016 Jun; 534(7607):305-6. PubMed ID: 27306167
    [No Abstract]   [Full Text] [Related]  

  • 13. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
    Mayer M
    Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
    [No Abstract]   [Full Text] [Related]  

  • 14. Settlement reached over medicaid coverage of cystic fibrosis drug: Arkansas federal court case highlights medical necessity, high cost of targeted therapies.
    Am J Med Genet A; 2015 Apr; 167A(4):viii-ix. PubMed ID: 25820402
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 16. New cystic fibrosis drug paves the way for orphan diseases.
    Cooney D
    Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084
    [No Abstract]   [Full Text] [Related]  

  • 17. Affordable prescription drugs--state and federal action.
    Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug combination that corrects deficient protein in cystic fibrosis improves lung function.
    Mayor S
    BMJ; 2015 May; 350():h2689. PubMed ID: 25990552
    [No Abstract]   [Full Text] [Related]  

  • 19. Vertex CF data wow Wall Street.
    Nat Biotechnol; 2017 Sep; 35(9):807. PubMed ID: 28898228
    [No Abstract]   [Full Text] [Related]  

  • 20. Foundation receives $3.3-billion windfall for Kalydeco.
    Senior M
    Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.